vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Postal Realty Trust, Inc. (PSTL). Click either name above to swap in a different company.
Postal Realty Trust, Inc. is the larger business by last-quarter revenue ($26.0M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). Postal Realty Trust, Inc. runs the higher net margin — 17.9% vs -0.8%, a 18.7% gap on every dollar of revenue. On growth, Postal Realty Trust, Inc. posted the faster year-over-year revenue change (21.7% vs -25.7%). Postal Realty Trust, Inc. produced more free cash flow last quarter ($37.6M vs $-15.8M). Over the past eight quarters, Postal Realty Trust, Inc.'s revenue compounded faster (22.6% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Postal Realty Trust, Inc. is a specialized real estate investment trust that acquires, owns, and manages properties primarily leased to the United States Postal Service. Its portfolio includes last-mile postal facilities, sorting centers, and retail post office locations across the U.S., supporting critical mail and package delivery infrastructure.
CTMX vs PSTL — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $26.0M |
| Net Profit | $-154.0K | $4.6M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 39.2% |
| Net Margin | -0.8% | 17.9% |
| Revenue YoY | -25.7% | 21.7% |
| Net Profit YoY | 97.6% | 3.1% |
| EPS (diluted) | — | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $26.0M | ||
| Q3 25 | — | $24.3M | ||
| Q2 25 | $18.7M | $23.4M | ||
| Q1 25 | $50.9M | $22.1M | ||
| Q4 24 | $38.1M | $21.4M | ||
| Q3 24 | $33.4M | $19.7M | ||
| Q2 24 | $25.1M | $18.1M | ||
| Q1 24 | $41.5M | $17.3M |
| Q4 25 | — | $4.6M | ||
| Q3 25 | — | $3.8M | ||
| Q2 25 | $-154.0K | $3.6M | ||
| Q1 25 | $23.5M | $2.1M | ||
| Q4 24 | $18.9M | $4.5M | ||
| Q3 24 | $5.7M | $1.1M | ||
| Q2 24 | $-6.5M | $817.0K | ||
| Q1 24 | $13.8M | $206.0K |
| Q4 25 | — | 39.2% | ||
| Q3 25 | — | 37.6% | ||
| Q2 25 | -6.9% | 37.3% | ||
| Q1 25 | 44.4% | 28.4% | ||
| Q4 24 | 46.4% | 43.2% | ||
| Q3 24 | 12.3% | 24.3% | ||
| Q2 24 | -33.7% | 22.8% | ||
| Q1 24 | 28.1% | 17.6% |
| Q4 25 | — | 17.9% | ||
| Q3 25 | — | 15.7% | ||
| Q2 25 | -0.8% | 15.5% | ||
| Q1 25 | 46.2% | 9.4% | ||
| Q4 24 | 49.6% | 21.1% | ||
| Q3 24 | 17.2% | 5.4% | ||
| Q2 24 | -26.0% | 4.5% | ||
| Q1 24 | 33.3% | 1.2% |
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.13 | ||
| Q2 25 | — | $0.12 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.17 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $0.02 | ||
| Q1 24 | — | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $1.5M |
| Total DebtLower is stronger | — | $361.1M |
| Stockholders' EquityBook value | $119.9M | $285.2M |
| Total Assets | $175.1M | $759.1M |
| Debt / EquityLower = less leverage | — | 1.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.5M | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | $49.0M | $1.1M | ||
| Q1 25 | $47.6M | $639.0K | ||
| Q4 24 | $38.1M | $1.8M | ||
| Q3 24 | $40.6M | $970.0K | ||
| Q2 24 | $43.2M | $1.7M | ||
| Q1 24 | $36.2M | $1.9M |
| Q4 25 | — | $361.1M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $328.8M | ||
| Q1 25 | — | $306.7M | ||
| Q4 24 | — | $296.7M | ||
| Q3 24 | — | $277.0M | ||
| Q2 24 | — | $273.7M | ||
| Q1 24 | — | $247.6M |
| Q4 25 | — | $285.2M | ||
| Q3 25 | — | $273.9M | ||
| Q2 25 | $119.9M | $250.8M | ||
| Q1 25 | $25.0M | $245.5M | ||
| Q4 24 | $-456.0K | $251.3M | ||
| Q3 24 | $-23.5M | $245.6M | ||
| Q2 24 | $-31.2M | $245.5M | ||
| Q1 24 | $-31.7M | $248.1M |
| Q4 25 | — | $759.1M | ||
| Q3 25 | — | $735.2M | ||
| Q2 25 | $175.1M | $689.8M | ||
| Q1 25 | $98.5M | $654.0M | ||
| Q4 24 | $120.5M | $646.8M | ||
| Q3 24 | $139.0M | $615.1M | ||
| Q2 24 | $159.2M | $608.2M | ||
| Q1 24 | $184.7M | $584.1M |
| Q4 25 | — | 1.27× | ||
| Q3 25 | — | 1.27× | ||
| Q2 25 | — | 1.31× | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | — | 1.18× | ||
| Q3 24 | — | 1.13× | ||
| Q2 24 | — | 1.11× | ||
| Q1 24 | — | 1.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $44.5M |
| Free Cash FlowOCF − Capex | $-15.8M | $37.6M |
| FCF MarginFCF / Revenue | -84.6% | 144.5% |
| Capex IntensityCapex / Revenue | 0.1% | 26.7% |
| Cash ConversionOCF / Net Profit | — | 9.59× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $65.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $44.5M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | $-15.8M | $11.4M | ||
| Q1 25 | $-21.0M | $10.8M | ||
| Q4 24 | $-19.9M | $33.5M | ||
| Q3 24 | $-20.7M | $8.0M | ||
| Q2 24 | $-19.5M | $9.9M | ||
| Q1 24 | $-26.0M | $6.4M |
| Q4 25 | — | $37.6M | ||
| Q3 25 | — | $8.8M | ||
| Q2 25 | $-15.8M | $9.1M | ||
| Q1 25 | $-21.2M | $10.2M | ||
| Q4 24 | $-20.0M | $30.7M | ||
| Q3 24 | $-20.7M | $7.4M | ||
| Q2 24 | $-19.6M | $8.9M | ||
| Q1 24 | $-26.2M | $5.8M |
| Q4 25 | — | 144.5% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | -84.6% | 38.8% | ||
| Q1 25 | -41.6% | 45.9% | ||
| Q4 24 | -52.5% | 143.8% | ||
| Q3 24 | -62.1% | 37.6% | ||
| Q2 24 | -78.2% | 49.4% | ||
| Q1 24 | -63.1% | 33.6% |
| Q4 25 | — | 26.7% | ||
| Q3 25 | — | 8.9% | ||
| Q2 25 | 0.1% | 10.1% | ||
| Q1 25 | 0.2% | 3.0% | ||
| Q4 24 | 0.2% | 13.0% | ||
| Q3 24 | 0.1% | 3.2% | ||
| Q2 24 | 0.4% | 5.4% | ||
| Q1 24 | 0.3% | 3.5% |
| Q4 25 | — | 9.59× | ||
| Q3 25 | — | 2.87× | ||
| Q2 25 | — | 3.16× | ||
| Q1 25 | -0.89× | 5.20× | ||
| Q4 24 | -1.05× | 7.44× | ||
| Q3 24 | -3.61× | 7.48× | ||
| Q2 24 | — | 12.10× | ||
| Q1 24 | -1.89× | 31.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
PSTL
Segment breakdown not available.
